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Objectives. 'e purpose of our survey is to analyze the clinical approach used by interventional and imaging cardiologists to
diagnose, treat, and follow-up patients with PFO-related left circulation thromboembolism in different parts of the world with
particular emphasis on adherence to current guidelines. Background. Firm guidelines do not cover many aspects of PFO-related
patient care. Consequently, very disparate approaches exist among clinicians in the real-world. Methods. A 24-item electronic
questionnaire was sent directly to experienced cardiology specialists practicing at consultant/attending positions directly involved
in PFO closure management in the United States, United Kingdom, Gulf countries, and other countries. 'ere were no
unanswered questions. Responses were recorded between October 2019 and July 2020. Results. Seventy-one responses were
obtained: 31 from the UK, 19 from the US, 16 from Gulf countries, 2 from Poland, and 1 response from Australia, Italy, and
Switzerland. 'e overall response rate was 76%. Significant differences between regions were noted in the duration of ECG
monitoring during the diagnostic process, PFO closure for left circulation thromboembolism other than stroke/transient ischemic
attack, and intraoperative use of intracardiac echocardiography. A similar pattern was noted in the lack of routine screening for
thrombophilia and the use of the long-term single antiplatelet therapy. Conclusions. 'e study shows a vast spectrum of opinions
on the optimal approach to PFO closure with significant differences between the US, UK, and Gulf countries.'e results stress the
need for systematic, high-quality data on the diagnostic work-up and follow-up strategies to inform the standardized approach.
1. Introduction
'e recent publications of long-term outcomes from ran-
domized controlled trials and meta-analyses confirm the
efficacy of PFO closure in mitigating the risk of recurrent
ischemic stroke compared with the antiplatelet therapy alone
in patients with cryptogenic stroke [1–5]. Based on the
review of best available evidence from trials and non-
randomized data, the European Society of Cardiology (ESC)
issued a position study on the management of patients with
PFO and systemic thromboembolism in order to guide a
rational approach to PFOmanagement from the index event
to follow-up [6]. 'e experts acknowledged very disparate
approaches among clinicians in the real-world and stressed
the need for urgent evaluation. 'erefore, we aimed to
capture the contemporary routine clinical practice of car-
diologists specializing in PFO management and their ad-
herence to key recommendations on an international level.
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2. Methods
2.1. Study Design. A 24-item electronic questionnaire con-
sisting of multiple choice (single or multiple answers) or
open-ended questions was devised to identify practice
patterns in three core areas: patient screening, procedure,
and follow-up (online supplement). Senior authors identi-
fied and contacted suitable respondents in their country/
region of practice. 'e survey was sent directly to subjects in
the e-mail alongside a covering letter meeting the informed
consent requirements. All respondents were experienced
cardiology specialists practicing as consultant/attending
physicians, and each of them was directly involved in PFO
closure procedures either as the operator, imaging specialist,
or in both roles. 'ere were no unanswered questions.
Responses were recorded between October 2019 and July
2020. 'e study was exempt from ethical approval on the
grounds of informed consent, voluntary participation, and
warrant of confidentiality.
2.2. Statistical Analysis. Data analysis was performed with
SPSS, version 26.0 (IBM Corporation, Armonk, NY). Cat-
egorical variables are presented as numbers and percentages
and compared using Fisher’s exact test. Continuous vari-
ables are presented as median (interquartile range) and
compared using the Kruskal–Wallis test. Post hoc pairwise
comparisons were performed after significant effects have
been found and were adjusted using the Bonferroni method.
P< 0.05 was considered statistically significant.
3. Results
Seventy-one responses were obtained from different parts of
the world: 31 from the UK, 19 from the US, 16 from Gulf
countries, 2 from Poland, and 1 response from Australia,
Italy, and Switzerland (Figure 1(a)). 'e overall response
rate was 76%. Regional differences between the US, UK, and
Gulf countries are presented in Table 1. Experience of ten or
more years in PFO closure was declared by nearly three-
quarters of respondents (n� 52, 73%); median length of
experience was 13 (7–19) years. 'e majority of respondents
were interventional cardiologists (n� 55, 77%) followed by
imaging specialists (n� 7, 10%), while 9 (13%) respondents
had expertise both in PFO intervention closure and imaging.
'e median population served was 2.8 (1.6–5) million in-
habitants, and annual operator volume was 33 (15–49)
patients at the time of the survey.
3.1. Preprocedural DiagnosticWork-Up and Patient Selection.
Silent atrial fibrillation (AF) as the cause for thromboem-
bolism was excluded with the use of 7–30-day continuous
ECG monitoring (n� 39, 55%), escalated to insertable car-
diac monitor (ICM) if appropriate (n� 17, 24%). 'e rest of
the respondents (n� 32, 45%) felt that short-term ECG
Holter monitoring ranging from 1 to 5 days was sufficient.
6% of respondents required a routine full screen for hy-
percoagulable disorders before PFO closure, 27% required
screening only in patients with relevant family history, and
68% declared not to screen for thrombophilia. 'ree-
quarters of respondents performed PFO closure in patients
who were above 60 years of age, and two-thirds performed
PFO closure in patients who had a typical transient ischemic
attack (TIA) with normal brain diffusion-weighted MRI
following a positive bubble study and “high-risk” features for
paradoxical embolism. PFO closure for left circulation
thromboembolism to organs other than the brain was
performed by 45 (63%) of whom 37 mentioned coronary
arteries; 25, extremity; 16, retina; 12, mesenteric artery/in-
testine; 9, spleen; 2, kidney; and 1, spinal cord. 'e Para-
doxical Embolism (RoPE) Score was used routinely by 20%
and occasionally by 41%. Figure 1(b) shows the specialists
present at a multidisciplinary team (MDT) panel. 'e
majority included interventional cardiologists and stroke
physicians or neurologists but less than half included an
imaging specialist. Seven respondents declared not to use an
MDTprocess as their cases were already multidisciplinary at
the point of referral.
3.2. Imaging and Procedural Technique. Transoesophageal
echocardiogram (TOE) was used by 69% of respondents to
characterize the PFO and risk stratify in the diagnostic
phase. Transcranial Doppler was available for 23 (32%) of
respondents. Six used it as a first-line imaging modality, 13
when the bubble study was equivocal or negative and the
remainder rarely or never.
Intracardiac echocardiography and 3D imaging were
used during the procedure by less than half (45% and 37%)
of respondents, and the Amplatzer device was used by the
majority (87%) (Figure 1(c)). 'e majority (61%) indicated
that they deploy the device via the PFO tunnel, and if this
fails, they then perform a transseptal puncture (TSP). A
minority (6%) performed transseptal puncture without
trying to deploy the device through the PFO tunnel, but 11%
of respondents do not perform TSP and would not close very
long tunnel defects percutaneously.
3.3. Follow-Up. Regarding approach to a residual shunt, the
majority (n� 41, 58%) of respondents repeat bubble echo-
cardiogram every 6–12 months until shunt closes, 26 (37%)
start or continue dual antiplatelet agents, and 6 (8%) switch to
anticoagulation. 'irteen (18%) cardiologists consider im-
plantation of a second PFO device, if feasible (Figure 1(d)).
Eighteen (25%) cardiologists undertake routine screening
with Holter ECGmonitoring for a new-onset atrial fibrillation
after device implantation.'e general approach to antiplatelet
therapy was as follows: 97% proposed dual antiplatelet
therapy (DAPT) for 1–6 months after PFO closure, and 63%
continued single antiplatelet therapy (SAPT) for at least five
years (Figure 1(e)). A repeat bubble echocardiogram for re-
sidual PFO was routinely performed by 27% at three months,
41% at six months, and 8% at twelve months.
3.4. Future Directions. PFO closure for primary prevention
in patients with a very high risk of paradoxical embolization
or cryptogenic ischemic stroke was declared by 11 (15%)
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Antiplatelet therapy aer PFO closure
6 months DAPT + SAPT for ≥5 years: 45.1 %
1 month DAPT + SAPT for ≥ 5 years: 18.3 %
1 month DAPT + 1 month SAPT: 1.4 %
1 month DAPT + SAPT until 6 months: 9.9 %
1 month DAPT + SAPT until 12 months: 9.9 %
6 months DAPT + SAPT until 12 months: 11.3 %
1 month DAPT : 1.4 %
no antiplatelet therapy: 1.4 %
(e)
Figure 1: (a) Map showing the distribution of responses. (b) 'e presence of different specialists at multidisciplinary team meeting. (c)
Patent foramen ovale devices used by the respondents. (d) Residual shunt occlusion. (e) Choice of drug therapy after patent foramen ovale
closure. ACHD, adult congenital heart disease; DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy.
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respondents, all were non-US based. In addition, 76% of
cardiologists performed PFO closure in one or more of the
following indications: decompression sickness, migraine
with aura, and platypnea-orthodeoxia syndrome.
4. Discussion
To our knowledge, it is the first survey capturing opinions of
consultant cardiologists directly involved in PFO closure in
different parts of the world. 'e previous survey on PFO
closure practice included 120 physicians in the UK, the vast
majority of whom were noncardiologists [7]. 'is survey
provides an insight into current clinical practice related to
selection and management in patients with left circulation
thromboembolism and shows how varied cardiologists’
practice is regarding PFO closure. 'e evidence base for PFO
closure for secondary prevention in patients with left circu-
lation thromboembolism has been elusive, and it is only
recent that an official position study has been published [6].
Everything prior to this had been expert opinion rather than
the fact, and this likely accounts for the considerable variation
in clinical practice as observed in this survey.
Based on the responses from the UK, the US, and Gulf
countries, we show that there is no standard approach to
patient selection, work-up, and follow-up on the interna-
tional level. In the UK, the commissioning policy for PFO
closure as secondary prevention following cerebrovascular
accident requires patients to be below the age of 60 and
recommends that TIA be supported by imaging evidence of
cerebral infarction, as per the criteria used for clinical trials
[8]. Our results demonstrate that most respondents in the
UK and elsewhere have performed PFO closure in patients
above 60 years of age and in TIA patients without an MRI
footprint. 'e UK Commissioning Policy also recommends
that all patients will be discussed at MDTconsisting of stroke
specialist and interventional cardiologist with expertise in
PFOmanagement, and hereby, we show good compliance to
this guidance by UK cardiologists [8]. Preferential use of at
least 7-day ECG monitoring including patch-type devices
and ICM to detect preexisting occult AF was declared, and
this is likely to become more widespread, given the growing
evidence base for extensive heart rhythm surveillance [9].
PFO closure has been associated with a four to five-fold
increased risk of AF development compared with medical
management [10, 11]. 'e latest meta-analysis showed that
the magnitude of risk occurs within the first 45 days (27.2
patients per 100 patient-years) compared with the period
after 45 days (1.3 patients per 100 patient-years).10 'e risk
of PFO device-associated stroke during this period appears
to be low, however, not negligible [11]. Regarding the choice
of drug therapy after PFO closure, the responses are mainly
in line with ESC recommendations; almost all respondents
routinely use 1–6 months of DAPT, and the majority
continued SAPT for at least five years. 'e responses varied
significantly as to whether follow-up echocardiography
looking at residual shunt should be performed and what
Table 1: Differences between the United Kingdom, United States, and Gulf countries with respect to key aspects of PFOmanagement (based
on 66 responses).
Parameter US (n� 19) UK(n� 31)
Gulf
(n� 16) P value
Respondents’ characteristics
Experience (years) 18 (10–20)∗ 11 (10–15) 5 (3–13)∗ 0.004
Population size of a PFO service 1.5 (1–5)∗† 3 (2–5)∗ 5 (2–23)† 0.002
Interventional cardiologists (PFO operators) 19 (100%)∗ 31 (100%)† 10 (63%)∗† <0.001
Annual volume 40 (20–75)∗ 40 (30–50)† 10 (5–18)∗† <0.001
Screening and patient selection
No screening for thrombophilia 5 (26%) 6 (19%) 2 (13%) 0.616
≥7-day ECG monitoring to exclude AF including use of ICM 18 (95%)∗† 12 (39%)∗ 7 (44%)† <0.001
PFO closure in patients older than 60-year-old 18 (95%)∗ 24 (77%) 7 (44%)∗ 0.002
PFO closure in patients with typical TIA, high-risk features, and negative brain DW-
MRI 13 (68%) 19 (61%) 9 (56%) 0.720
PFO closure of left circulation thromboembolism other than stroke/TIA 10 (53%)∗ 28 (90%)∗† 3 (19%)† <0.001
Occasional or regular use of the RoPE score 15 (79%) 14 (45%) 13 (81%) 0.013
Routine TOE before PFO closure procedure 13 (68%) 16 (52%)∗ 15 (94%)∗ 0.009
Availability of transcranial Doppler 9 (47%) 6 (19%) 4 (25%) 0.127
Procedure and follow-up
Intraoperative use of ICE 18 (95%)∗† 11 (36%)∗ 3 (19%)† <0.001
Continuation of single antiplatelet therapy for at least 5 years 13 (68%) 21 (68%) 9 (63%) 0.891
Repeat bubble echocardiogram postdischarge 16 (84%) 24 (77%) 10 (56%) 0.170
Future directions
PFO closure as a primary prevention 0 (0%) 6 (19%) 3 (19%) 0.050
PFO closure for decompression sickness/migraine with aura/platypnea-orthodeoxia
syndrome 16 (84%)
∗ 30 (97%)† 5 (31%)∗† <0.001
Values are median (IQR) or n (%). ∗ and † denote the significant difference in post hoc pairwise comparison using Bonferroni correction at adjusted p
value< 0.05. AF, atrial fibrillation; DW-MRI, diffusion-weighted magnetic resonance imaging; ECG, electrocardiogram; ICE, intracardiac echocardiography;
ICM, insertable cardiac monitor; PFO, patent foramen ovale; RoPE, Risk of Paradoxical Embolism TOE, transoesophageal echocardiography; TIA, transient
ischemic attack.
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time frame is the most appropriate. A previous study shows
that residual shunt is present in up to 25% of patients after
PFO closure [12]. At present, there is a paucity of data on the
optimal approach to residual shunt [6]. We have found a
broad spectrum of approaches to residual shunt manage-
ment, ranging from no action, antiplatelet agents, or anti-
coagulants to repeat closure with a second device. In the
authors’ opinion, in patients with a residual shunt, long-
term SAPT should be maintained life-long, while we await
further follow-up data.
Approximately one-fifth of UK and Gulf-based re-
spondents declared having closed PFO for primary pre-
vention of paradoxical systemic embolism, whereas none in
the US. Undoubtedly, at present, there is no trial data to
support this concept. On the other hand, it has been pos-
tulated that PFO closure may be beneficial in patients with
high-risk anatomical PFO characteristics and a history of
venous thromboembolism [13]. US and UK respondents
have reported closing PFO for decompression sickness,
migraine with aura, and platypnea-orthodeoxia syndrome.
'e circumstances where PFO closure might be considered
in these conditions above have been summarised in the
second part of the ESC position statement [14]. Given the
weak current evidence, the multidisciplinary group of ex-
perts have urged that new prospective observational and
randomized studies are needed to obtain more definitive
evidence. Also, local registries providing prospective eval-
uations of outcomes were strongly encouraged.
5. Limitations
'e survey insights should be interpreted cautiously as a
snapshot of contemporary practice. We used purposive,
nonrandom sampling to deliberately target individuals es-
pecially knowledgeable about and experienced with PFO
management. While the response rate was satisfactory, the
inability to identify and reach all suitable clinicians in re-
gions of interest is a potential source of bias. Nevertheless, to
our best knowledge, there had been no systematic difference
in characteristics between responders and nonresponders;
hence, nonresponse bias would most likely not have oc-
curred. 'e specific differences in the survey results, such as
length of ECG monitoring to look for preexisting occult AF,
availability of ICE, and PFO closure devices, are likely due to
different reimbursement models used in the three regions.
6. Conclusions
'e study shows a very broad spectrum of opinions on the
optimal approach to PFO closure. 'e results stress the need
for systematic, high-quality data on the diagnostic work-up
and follow-up strategies to inform a standardized approach.
In particular, studies on the significance and optimal ap-
proach to residual shunt are warranted.
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